Metrics as of 10/15/2026, 02:17 PM (Berlin time), refresh in progress.
Entrada Therapeutics Stock
Entrada Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dipal Doshi
- Employees
- 152
- Market cap
- $177 M
- IPO
- 29/10/2021
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs,…
Entrada Therapeutics stock: price history
1D
-6.4%
1W
-18.9%
1M
-35.5%
6M
-67.5%
YTD
-55.7%
1Y
-24.9%
2Y
-74.5%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~61% stronger price swings than usual
Ask the agents about Entrada Therapeutics
Analyst assessment of Entrada Therapeutics
PRICE TARGET LOW
US$11.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 08/06/2026
Entrada Therapeutics stock metrics
P/E
-1.15
P/B
0.82
EV/EBITDA
-0.77
RETURN ON EQUITY
-18.3%
NET MARGIN
-4,762.0%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
58.2%
FLOAT SHARES
22,668,665
AVG. DAILY VOLUME (30D)
346,460
Insider transactions (SEC)
MPM BioVentures 2014, L.P.
MPM BioVentures 2014, L.P.
MPM BioVentures 2014, L.P.
MPM BIOVENTURES 2018, L.P.
MPM BIOVENTURES 2018, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Entrada Therapeutics stock
What does Entrada Therapeutics do?
Entrada Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dipal Doshi, the company employs around 152 people.
The IPO was on 29/10/2021; the stock trades on NASDAQ under the ticker TRDA.
What do analysts say about Entrada Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 08/06/2026).
The average price target is US$14.00, ranging from US$11.00 to US$17.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does Entrada Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 61% stronger than usual.
Does Entrada Therapeutics pay a dividend?
No, Entrada Therapeutics currently does not pay a dividend.
Which stocks are comparable to Entrada Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Entrada Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Entrada Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.